123696澳门论坛

09.02

EDG Announced EDP167 has successfully completed the first subject dosing in its Phase II clinical trial

30.12

EDDING Group and Genor Bio have completed the merger

05.07

EDDING Announces NMPA Approval Of VASCEPA? (Icosapent Ethyl) For New Cardiovascular Risk Reduction (CVRR) Indication in Mainland China

15.11

NMPA Accepts Marketing Application for VASCEPA? (icosapent ethyl) Cardiovascular Risk Reduction (CVRR) Indication

29.06

EDDING Recives Regulatroy Approval For MULPLETA? (Lusutrombopag Tablets) in Mainland China

01.06

EDDING Receives Regulatory Approval For VASCEPA? (Icosapent Ethyl) in Mainland China

16.01

Lusutrombopag Phase III Study Results in Mainland China was published on Hepatology International